Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13351664 | 0.73 | CYP3A4 (0.33) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL1082749 | 0.71 | CYP3A4 (0.41) | CYP3A4APPTSHRMAPTCACNA1B | |
| SCHEMBL9286605 | 0.71 | MAPT (0.36) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL6695619 | 0.71 | CYP3A4 (0.38) | CYP3A4APPTSHRMAPTCACNA1B | |
| SCHEMBL28427366 | 0.70 | CYP3A4 (0.39) | CYP3A4APPTSHRMAPTCACNA1B | |
| SCHEMBL822080 | 0.70 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL29506833 | 0.70 | CYP3A4 (0.39) | CYP3A4APPTSHRMAPTCACNA1B | |
| SCHEMBL11444238 | 0.70 | CYP3A4 (0.39) | CYP3A4APPTSHRMAPTCACNA1B | |
| SCHEMBL31732818 | 0.70 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL28761387 | 0.70 | CYP3A4 (0.39) | CYP3A4APPTSHRMAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470810-B2 | Alkyl and aryl-thiotrifluoroacetates and process | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | claimed |
| WO-2005073185-A1 | NOVEL ALKYL- AND ARYL-THIOTRIFLUOROACETATES AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050159612-A1 | Novel alkyl- and aryl-thiotrifluoroacetates and process | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-21 | — | — | US | claimed |
| US-7470810-B2 | Alkyl and aryl-thiotrifluoroacetates and process | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2005073185-A1 | NOVEL ALKYL- AND ARYL-THIOTRIFLUOROACETATES AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050159612-A1 | Novel alkyl- and aryl-thiotrifluoroacetates and process | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159612-A1 | Novel alkyl- and aryl-thiotrifluoroacetates and process | TAF9, TAF1, TAF1L | CYP3A4 3236/4885APP 2274/4885TSHR 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.